CBD in cosmetic products

2024-03-11T13:01:18+00:00March 11th, 2024|

The European Commission has opened a public consultation as a call for data on the safety of Cannabidiol (CBD) in cosmetic products, within the framework of legislation 1223/2009.

MHRA First IRP Approval

2024-03-05T14:42:41+00:00March 6th, 2024|

The MHRA has announced the first authorisation via the International Recognition Procedure (IRP). The approval, granted within a 30-day timeframe, marks a milestone in accelerating the availability of essential medications for UK patients.

Codeine linctus from P to POM

2024-02-26T14:40:44+00:00February 27th, 2024|

The Medicines and Healthcare products Regulatory Agency (MHRA) has released a consultation on the potential reclassification of codeine linctus to a prescription-only medicine.

EMIG Quarterly Meeting Review

2024-02-26T12:22:20+00:00February 26th, 2024|

Janet Worrell attended the Ethical Medicines Industry Group (EMIG) quarterly meeting on 19th February 2024 and heard directly from Julian Beach, the Interim Executive Director for Healthcare Quality and Access from the MHRA.

EMC webinar

2024-02-20T16:13:48+00:00February 21st, 2024|

In a recent webinar, members of the Datapharm team delved into the accessibility of the Electronic Medicines Compendium (EMC) for healthcare professionals (HCPs) and patients/carers. The discussion brought to light compelling statistics that shed light on user behaviour and preferences when accessing medical information online.

Combination Products

2024-02-15T15:10:16+00:00February 20th, 2024|

Combination products have complex regulatory pathways. Changes to EU regulations mean the way Drug-Device Combination products are regulated now involves notified bodies. With strong medicines and medical device teams, read how JensonR+ are expert in supporting combination products.

The Windsor Framework: Centralised Products and Northern Ireland

2024-01-30T09:18:27+00:00January 25th, 2024|

The EMA has recently published a Q&A guide on the implementation of Regulation (EU) 203/1182 and the potential need by Marketing Authorisation Holders to prepare in advance any regulatory, labelling and/or supply changes required for its implementation to help ensure the continuous supply of the product.

DDC Case Study

2024-01-18T14:16:09+00:00January 19th, 2024|

Read how JensonR+ supported an established pharmaceutical company based in the EU launching a new drug-device combination product in Europe and the UK.

Portfolio Management Services

2024-01-23T08:52:12+00:00January 17th, 2024|

Before placing General Foods, Fortified Foods, Food Supplements, Food for Special Medical Purposes (FSMPs) or other Foods for Special Groups (including meal replacement products) on the market, regulatory due diligence must be performed to ensure compliance with applicable regulations in terms of composition and presentation to the final consumer. Find out how JensonR+ can help.

Go to Top